Tirzepatide and Sleep Apnea: What the Human Trials Found
Weight Loss & Metabolism Research
In two 2024 New England Journal of Medicine trials in 469 adults with obesity and moderate-to-severe obstructive sleep apnea, tirzepatide cut breathing interruptions by 25 to 29 an hour over a year, against about 5 on placebo. In December 2024 it became the first medicine approved by the US Food and Drug Administration for moderate-to-severe sleep apnea in adults with obesity. Here is the tirzepatide sleep apnea record: the trials, the follow-up analyses, how it compares with other treatments, and the newer reta (GLP-3) data.
View product →Findings
- Over 52 weeks, tirzepatide lowered the apnea-hypopnea index (AHI) by 25.3 and 29.3 events per hour in the two trials, against 5.3 and 5.5 on placebo, from starting levels of about 50 (NEJM, 2024).
- Every prespecified key secondary endpoint improved: body weight, hypoxic burden, sleep impairment and sleep disturbance scores, the inflammation marker hsCRP and systolic blood pressure.
- 42% to 50% of participants on tirzepatide reached disease remission (JAMA Otolaryngology review, 2026).
- Across 41 placebo-controlled trials of 37 drugs and combinations tested for sleep apnea, tirzepatide produced the largest AHI reduction (Sleep Medicine Reviews, 2025).
The tirzepatide sleep apnea trials
Obstructive sleep apnea is repeated collapse of the upper airway during sleep. It affects up to 1 billion people worldwide and is frequently driven by excess weight (Malhotra et al., Sleep Med, 2025); obesity is present in 60% to 70% of people with the condition (Harris and Kaffenberger, JAMA Otolaryngol Head Neck Surg, 2026). Tirzepatide is a once-weekly peptide that activates two gut-hormone receptors, GIP and GLP-1.
The two trials ran under one master protocol. In all, 469 adults with moderate-to-severe sleep apnea (an AHI of at least 15 events per hour) and obesity (a BMI of at least 30) were randomised 1:1 to tirzepatide or placebo. The first trial enrolled 234 people who were not using positive airway pressure (PAP); the second enrolled 235 who were. Everyone also followed a lifestyle program for weight reduction (Malhotra et al., Contemp Clin Trials, 2024), and people on tirzepatide received the highest dose they tolerated for 52 weeks.
The AHI counts apneas and hypopneas, full and partial pauses in breathing, per hour of sleep. Mean BMI at the start was 39.1 in the first trial and 38.7 in the second (Malhotra et al., N Engl J Med, 2024).
| AHI, events per hour | Trial 1 (no PAP) | Trial 2 (on PAP) |
|---|---|---|
| Starting AHI | 51.5 | 49.5 |
| Change on tirzepatide | -25.3 | -29.3 |
| Change on placebo | -5.3 | -5.5 |
| Difference | -20.0 | -23.8 |
Both differences were statistically significant (P<0.001). In the second trial, PAP was withdrawn before the sleep studies and questionnaires, so those measurements were taken without the machine (Kanu et al., Sleep Med, 2025). The most common side effects on tirzepatide were gastrointestinal, mostly mild to moderate.
What improved beyond the AHI
Every prespecified key secondary endpoint improved significantly against placebo: percent change in AHI, body weight, hypoxic burden (how deeply and for how long oxygen falls during events), patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP, an inflammation marker) and systolic blood pressure.
A 2026 review reported that 42% to 50% of participants on tirzepatide reached disease remission, defined as an AHI below 5 events per hour, or below 15 without symptoms (Harris and Kaffenberger). In a 2026 post hoc analysis, 68% to 79% of tirzepatide participants moved to a milder AHI severity category, while most on placebo (64% to 70%) saw no clinically relevant change. AHI fell in every subgroup examined (age, sex, BMI, neck circumference and starting severity), by 12.1 to 52.2 events per hour across the severity groups (Falcon et al., J Clin Sleep Med).
Participants felt it too. At 52 weeks, tirzepatide improved PROMIS sleep-related impairment and sleep disturbance scores, the Functional Outcomes of Sleep Questionnaire, EQ-5D-5L and most domains of the SF-36 health survey, plus the Epworth Sleepiness Scale in the first trial (Kanu et al., 2025). Participants who started out sleepy gained most: in the first trial, their sleep-related impairment score improved by 7.1 points more than placebo, against 1.6 in those who were not sleepy (Kanu et al., Sleep, 2026). In exit interviews with 82 participants, more people on tirzepatide than on placebo reported meaningful improvement in key symptoms, and satisfaction was higher (Shinde et al., Patient, 2026).
How fast it worked, and why
Home sleep tests in the first trial showed the AHI improving against baseline as early as week 4, and the gap from placebo became significant at week 20. In both trials, the size of the improvement in AHI and hypoxic burden tracked the weight each participant lost (Malhotra et al., Sleep Med, 2025).
Weight loss is the main established mechanism: GLP-1-based peptides reduce fat in the tongue and around the throat that contributes to airway collapse. Early laboratory work also points to effects beyond weight, including GLP-1 receptors in the carotid body, which senses blood oxygen and helps set breathing control (Harris and Kaffenberger, 2026). A 2026 Nature Medicine analysis found that cardiometabolic risk factors improved more on tirzepatide than placebo in both trials, and that the sleep apnea improvements themselves, independently of weight, accounted for part of the falls in hsCRP, insulin resistance and triglycerides (Malhotra et al.).
How tirzepatide compares with other sleep apnea treatments
A 2025 Sleep Medicine Reviews analysis of 41 randomised placebo-controlled trials, covering 37 drugs and drug combinations tested for sleep apnea, found that tirzepatide produced the largest reduction in AHI and also improved patient-reported outcomes and cardiometabolic risk factors (Luu et al.). A 2026 network meta-analysis in Respiratory Medicine ranked tirzepatide first among newer diabetes drugs for AHI reduction (21.85 events per hour against control), and it also led on weight (19.41 kg) and blood pressure (Yang et al.).
A 2025 umbrella review in eClinicalMedicine placed tirzepatide second only to CPAP for lowering the AHI, at 21.86 events per hour against 30.7, with moderate-certainty evidence for tirzepatide and low-certainty evidence for CPAP. Mandibular advancement devices followed at 11.91 (Figard et al.).
Real-world tirzepatide sleep apnea data
A 2025 Chest study matched 42,300 adults with sleep apnea and obesity from health records: 21,150 prescribed tirzepatide and 21,150 managed with lifestyle measures. Tirzepatide use was associated with lower all-cause mortality (hazard ratio 0.443), fewer major cardiovascular events (0.731) and fewer major kidney events (0.427), an association rather than a trial result (Wu et al.).
Reta (GLP-3) and sleep apnea
Reta (GLP-3) adds a third target, the glucagon receptor, to tirzepatide’s two. In a phase 3 New England Journal of Medicine trial published in September 2026, 2,339 adults with obesity and without diabetes were randomised for 80 weeks; among the 243 with sleep apnea, the two higher-dose groups lowered the AHI by 24.4 and 21.9 events per hour more than placebo (Jastreboff et al.). More in reta vs tirzepatide.
Tirzepatide from Vistara Labs
Our tirzepatide is a 10 mg lyophilised vial, shipped from within Canada, and the guide to buying tirzepatide in Canada covers ordering. The tirzepatide reconstitution guide covers bacteriostatic water, and the peptide calculator does the arithmetic. For the wider record, see Tirzepatide Trials: Weight and Diabetes, GLP-1 for diabetes and tirzepatide vs semaglutide. Buy Tirzepatide
Tirzepatide and reta (GLP-3) are supplied for laboratory research use only. For more, browse Weight Loss and Metabolism Research.
Frequently asked questions
What has research on tirzepatide and sleep apnea shown?
In two 52-week trials in 469 adults with obesity and moderate-to-severe sleep apnea (NEJM, 2024), tirzepatide lowered the apnea-hypopnea index by 25.3 and 29.3 events per hour, against 5.3 and 5.5 on placebo. Body weight, hypoxic burden, sleep-related patient-reported outcomes, hsCRP and systolic blood pressure also improved.
What has research shown about sleep apnea remission with tirzepatide?
A 2026 review reported that 42% to 50% of participants on tirzepatide reached disease remission, defined as an AHI below 5 events per hour, or below 15 without symptoms. In a post hoc analysis, 68% to 79% of participants on tirzepatide moved to a milder severity category.
What has research shown about tirzepatide in people already using CPAP?
The second trial enrolled 235 adults already using positive airway pressure. With PAP withdrawn before testing, the AHI fell by 29.3 events per hour on tirzepatide against 5.5 on placebo over 52 weeks.
What has research shown about how quickly tirzepatide improved sleep apnea measures?
In the first trial, home sleep tests showed the AHI improving against baseline as early as week 4, and the difference from placebo became significant at week 20. In both trials, the size of the improvement tracked the weight each participant lost.
Where can I buy tirzepatide in Canada?
Vistara Labs supplies tirzepatide as a 10 mg lyophilised vial, plus reta (GLP-3), shipped from within Canada. Laboratory research use only.
Product specifications from vistaralabs.ca, October 2026. Sources: Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. PMID 38912654. Malhotra A et al. Contemp Clin Trials. 2024;141:107516. PMID 38547961. Kanu C et al. Sleep Med. 2025;134:106719. PMID 40774158. Malhotra A et al. Sleep Med. 2025;136:106853. PMID 41135142. Kanu C et al. Sleep. 2026:zsag184. PMID 42412744. Falcon B et al. J Clin Sleep Med. 2026;22(1):155. PMID 42675225. Malhotra A et al. Nat Med. 2026;32(2):653-659. PMID 41540105. Shinde S et al. Patients’ Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study. Patient. 2026. PMID 41793578. Harris A, Kaffenberger T. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review. JAMA Otolaryngol Head Neck Surg. 2026. PMID 42690639. Luu S et al. Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials. Sleep Med Rev. 2025. PMID 40974973. Yang YT et al. Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis. Respir Med. 2026. PMID 41616874. Figard C et al. Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials. EClinicalMedicine. 2025. PMID 41140453. Wu JY et al. Clinical Impact of Tirzepatide on Patients With OSA and Obesity. Chest. 2025. PMID 40254150. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID 42814954.
References
Tirzepatide has one of the largest human trial programmes of any compound in this catalogue, including multiple phase 3 trials.
- Tirzepatide Once Weekly for the Treatment of ObesityRandomised phase 3 trial; 2,539 adults with overweight or obesity without diabetes, 72 weeks.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityRandomised phase 3 withdrawal trial; 670 participants randomised after a 36-week open-label phase.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityRandomised phase 3 trials in adults with obesity and moderate-to-severe obstructive sleep apnoea.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityRandomised phase 3 trial (SUMMIT); 731 patients with obesity-related heart failure with preserved ejection fraction.
- Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysisSystematic review and meta-analysis; 22 trials, 29,023 participants.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
